Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don’t) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.